Form 8-K - Current report:
SEC Accession No. 0001641172-25-012395
Filing Date
2025-05-27
Accepted
2025-05-27 07:30:56
Documents
19
Period of Report
2025-05-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 58487
2 EX-4.1 ex4-1.htm EX-4.1 114347
3 EX-4.2 ex4-2.htm EX-4.2 118391
4 EX-4.3 ex4-3.htm EX-4.3 122969
5 EX-10.1 ex10-1.htm EX-10.1 275767
6 EX-10.2 ex10-2.htm EX-10.2 182974
7 EX-99.1 ex99-1.htm EX-99.1 16216
  Complete submission text file 0001641172-25-012395.txt   1235675

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE imnn-20250523.xsd EX-101.SCH 3008
9 XBRL LABEL FILE imnn-20250523_lab.xml EX-101.LAB 34239
10 XBRL PRESENTATION FILE imnn-20250523_pre.xml EX-101.PRE 22354
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3688
Mailing Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648
Business Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648 (609) 896-9100
Imunon, Inc. (Filer) CIK: 0000749647 (see all company filings)

EIN.: 521256615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-15911 | Film No.: 25984200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)